March 1, 2019 Clinical Research/Diagn. M&A, Partnerships

Crown Bioscience and The Jackson Laboratory Collaboration Enables Global Access to FATZO Mouse

Continued Collaboration Facilitates Global Distribution of Obesity, Metabolic Disease, and NASH Model and Priority Supply to CrownBio’s World-Class Cardiovascular, Obesity, and Metabolic Disease Platform San Diego, Calif. – March 5, 2019 – Crown Bioscience, a global drug discovery and development services company, providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research today announced... Read more

February 28, 2019 Clinical Research/Diagn. Lab Top-10 Life Science Tools M&A, Partnerships

Beckman Coulter Life Sciences Enters Liquid Biopsy Partnership with Apostle Inc.

Indianapolis, Indiana (February 28, 2019) – At the Advances in Genome Biology and Technology (AGBT) General Meeting*, Beckman Coulter Life Sciences announces the launch of Apostle MiniMax™ High Efficiency Cell-Free DNA Isolation Kit through an exclusive partnership with Apostle, a liquid biopsy company. As cfDNA workflows move beyond theoretical and into human health applications, Apostle’s industry leading chemistry... Read more

February 26, 2019 Clinical Research/Diagn. M&A, Partnerships

Bio-Techne Signs Strategic Cooperation Agreement With Lisen Imprinting Diagnostics

FEBRUARY 26, 2019 MINNEAPOLIS, Feb. 26, 2019 /PRNewswire/ — Bio-Techne has entered into a strategic cooperation agreement in the precision medicine field with Lisen Imprinting Diagnostics Wuxi Co., Ltd, China. Liwen Pei, Managing Director of Bio-Techne China, and Ning Zhou, CEO of Lisen, attended the meeting and signing ceremony. Bio-Techne is a leading provider of high-quality... Read more

February 26, 2019 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Thermo Fisher Scientific to Support mRNA-based Vaccine Candidate Production for BioNTech

Thermo Fisher Scientific to Support mRNA-based Vaccine Candidate Production for BioNTech Agreement ensures consistent supply of nucleotides, enzymes and other critical raw materials for messenger RNA (mRNA) vaccine manufacturing platform WALTHAM, Mass., Feb. 26, 2019 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, today announced it has signed a multi-year agreement with Mainz,... Read more

February 26, 2019 Clinical Research/Diagn. Lab Top-10

Thermo Fisher Scientific's Oncomine Dx Target Test Receives Expanded Regulatory Approval in Japan

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives Expanded Regulatory Approval in Japan Companion diagnostic test enables physicians to identify non-small cell lung cancer patients who may benefit from eight targeted therapies CARLSBAD, Calif., Feb. 26, 2019 /PRNewswire/ — Thermo Fisher Scientific today announced that the Ministry of Health, Labour and Welfare (MHLW), Japan’s regulatory agency,... Read more

February 25, 2019 Clinical Research/Diagn. M&A, Partnerships

Roche enters into definitive merger agreement to acquire Spark Therapeutics

Basel, 25 February 2019 Roche enters into definitive merger agreement to acquire Spark Therapeutics Roche to acquire Spark Therapeutics for US$ 114.50 per share Spark Therapeutics is a leader in discovering, developing and delivering gene therapies with one commercial asset and four programmes currently in clinical trials Transaction expected to close in Q2, 2019 Roche... Read more

February 14, 2019 Clinical Research/Diagn. Licensing, IP, and Legal Life Science Tools Product Launch

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response

Date: 02/14/2019 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug... Read more

February 12, 2019 Clinical Research/Diagn.

GE Healthcare and Preventice Solutions Collaborate to Connect the Heart, the Hospital and the Home Seamlessly

Orlando – Feb. 12, 2019 – GE Healthcare (NYSE:GE) is working with Preventice Solutions to give clinician tools to follow patients with known or suspected Atrial fibrillation virtually from hospital to home. Atrial fibrillation, or AF, is an irregular and often rapid heart rate that can increase risk of stroke, heart failure and other heart-related complications,... Read more

February 7, 2019 Cell Analysis Tools Clinical Research/Diagn. M&A, Partnerships Mass Spectrometry

Fluidigm Announces Participation in Life Science/Pharma and Academic Consortium to Study T Cell-Driven Immune-Mediated Inflammatory Diseases

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ: FLDM) today announced it is one of 11 partners in the TIMID Consortium, a unique effort of six academic institutions and five life science and pharma companies that utilizes both mass cytometry and Imaging Mass Cytometry™ along with other technologies to explore the common cellular basis of... Read more

February 7, 2019 Clinical Research/Diagn. M&A, Partnerships

Fluidigm Announces Co-Marketing Agreement with Indica Labs to Offer Platform for Imaging Mass Cytometry Data Analysis to Aid Novel Digital Pathology Investigations

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ: FLDM) and Indica Labs, Inc., today announced a co-marketing relationship for scalable and simple-to-use tissue image analysis for Imaging Mass Cytometry™ (IMC™). Under the terms of the agreement, Fluidigm and Indica Labs will cooperatively promote the next-generation digital pathology image analysis and image management platforms HALO®, HALO AI™and HALO Link™ in conjunction with... Read more